159 related articles for article (PubMed ID: 37119208)
1. The impact of relapse definition and measures of durability on MS clinical trial outcomes.
Satyanarayan S; Cutter G; Krieger S; Cofield S; Wolinsky JS; Lublin F
Mult Scler; 2023 Apr; 29(4-5):568-575. PubMed ID: 37119208
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
3. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L
JAMA Neurol; 2023 Nov; 80(11):1232-1245. PubMed ID: 37782515
[TBL] [Abstract][Full Text] [Related]
5. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
10. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
Chen B; Ji SQ; Shen F; Tian DS; Bu BT
Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
[TBL] [Abstract][Full Text] [Related]
11. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
Lepore V; Bosetti C; Santucci C; Iaffaldano P; Trojano M; Mosconi P;
Eur J Neurol; 2021 Feb; 28(2):567-578. PubMed ID: 33058344
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
14. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
17. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
18. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Koch MW; Moral E; Brieva L; Mostert J; Strijbis EM; Comtois J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Cutter G
Mult Scler; 2023 Dec; 29(14):1776-1785. PubMed ID: 37830451
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
20. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
J Neurol; 2024 May; ():. PubMed ID: 38805052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
